Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
WEBJun 20, 2024 · Gilead recognizes the importance of helping to enable access in order for twice-yearly lenacapavir for PrEP, if approved by regulatory authorities, to achieve the broadest impact.
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced …
WEBSep 12, 2024 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV).
Full Efficacy and Safety Results for Gilead ... - Gilead Sciences
WEBJul 24, 2024 · Overall, lenacapavir was highly effective among trial participants, with zero HIV infections observed in the lenacapavir group (0/100 person-years; 95% CI, 0.00 to 0.19) compared to background HIV incidence (bHIV) (2.41/100 person-years; 95% CI, 1.82 to 3.19), translating to a 100% reduction in HIV infections.
Twice-yearly shot proves successful at preventing HIV infection …
WEBJul 24, 2024 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
WEBJun 20, 2024 · Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention. June 20, 2024. – First Phase 3 HIV Prevention Trial Ever to Show Zero Infections –. – Independent Data Monitoring Committee Recommended That Gilead Stop the Blinded Phase of the PURPOSE 1 …
Gilead Sciences, Inc. - Sunlenca® (lenacapavir) Receives FDA …
WEBDec 22, 2022 · Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV. December 22, 2022. – Sunlenca is the First and Only Approved Capsid Inhibitor-Based HIV Treatment Option –. – New Drug Application Approval Based on High Rates of Sustained Virologic ...
Gilead’s lenacapavir: HIV prospects strongest in long-acting …
WEB4 days ago · Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced …
WEBSep 12, 2024 · Gilead is executing an access strategy that prioritizes speed and enables the most efficient paths for the regulatory review and approval of lenacapavir for PrEP in regions around the world.
Gilead Lenacapavir cut HIV infections by 96% in trial
WEBSep 12, 2024 · A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug. Gilead ’s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday ...
Gilead Sciences, Inc. - Gilead’s Twice-Yearly Lenacapavir for HIV ...
WEBSep 12, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir.